Who Exports Ketorolac from India — 351 Suppliers Behind a $115.9M Market

Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for Active Pharmaceutical Ingredients (APIs) production. The city contributes approximately 40% of India's pharmaceutical production and is responsible for 40% of the nation's total API output. This prominence is supported by a robust network of over 2,000 life sciences companies and 269 US FDA-approved facilities. The Telangana government's initiatives, such as the establishment of Genome Valley and the annual BioAsia summit, further bolster Hyderabad's position as a global center for pharmaceutical innovation and manufacturing.

The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat hosts 13 pharmaceutical clusters, with Ahmedabad and Vadodara being prominent centers. Companies like Alembic Pharmaceuticals, headquartered in Vadodara, exemplify the region's strength in producing finished dosage forms. Alembic Pharmaceuticals, established in 1907, operates manufacturing facilities in Gujarat and has a significant presence in both domestic and international markets.

The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for pharmaceutical products. Maharashtra leads India with 40 pharmaceutical clusters, facilitating extensive export activities. Sun Pharmaceutical Industries Limited, headquartered in Mumbai, is a prime example of the region's export prowess. As India's largest pharmaceutical company and the fourth-largest specialty generic pharmaceutical company globally, Sun Pharma's extensive manufacturing and distribution networks underscore the region's strategic importance in global pharmaceutical trade.

The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, primarily due to favorable tax incentives. The area hosts 555 pharmaceutical units, benefiting from excise duty exemptions and a well-developed industrial infrastructure. These advantages have attracted numerous pharmaceutical companies, making Baddi a preferred location for cost-effective manufacturing operations.

• Diversify Supplier Base: While major suppliers like GLAND PHARMA LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED dominate Ketorolac exports, consider engaging with emerging manufacturers in regions like Baddi to mitigate supply chain risks.

• Leverage Regional Specializations: Utilize Hyderabad's API production capabilities for raw material sourcing and Ahmedabad-Vadodara's expertise in formulations for finished products to optimize the supply chain.

• Monitor Regulatory Compliance: Ensure that suppliers, especially those in export-centric regions like Mumbai-Thane-Raigad, maintain compliance with international regulatory standards to facilitate seamless market access.

• Assess Cost Benefits: Evaluate the financial advantages offered by manufacturing clusters with tax incentives, such as Baddi-Nalagarh, to reduce production costs without compromising quality.

By strategically analyzing and engaging with India's diverse pharmaceutical clusters, companies can enhance their sourcing strategies for Ketorolac, ensuring a robust and efficient supply chain.